Brightness Acuity Testing After Endothelial Cell Therapy for Corneal Edema

By Dr. Matt Giegengack, Cornea Specialist at Wake Forest University

As a cornea specialist, I’m constantly seeking innovative treatments to improve the lives of my patients suffering from corneal edema. One such treatment that has shown great promise is endothelial cell therapy, a procedure that has the potential to address both vision clarity and bothersome glare associated with corneal edema.

The Need for Effective Glare Treatment

Traditionally, Descemet membrane endothelial keratoplasty (DMEK) has been the gold standard for treating Fuchs dystrophy and corneal edema, particularly due to its effectiveness in reducing glare. However, DMEK is not suitable for all patients, such as those with unstable lenses or specific glaucoma procedures. This limitation underscores the need for alternative treatments that can benefit a broader patient population.

Promising Results from El Salvadorian Trials

I’ve had the privilege of working with Aurion Biotech for the past four years, including participating in their clinical trials in El Salvador. While our previous presentations focused on best-corrected visual acuity, we’ve also analyzed brightness acuity testing results from these trials. These results are incredibly encouraging.

We observed a consistent improvement in both best-corrected visual acuity and brightness acuity at various time points over a one-year follow-up period. This suggests that endothelial cell therapy not only improves overall vision but also effectively reduces glare, much like DMEK.

Addressing the Challenges of Severe Disease

The El Salvadorian trial participants had more severe corneal edema compared to the patients in our ongoing US clinical trial. We anticipate that the US trial, which focuses on less severe cases, will further solidify the effectiveness of endothelial cell therapy for treating glare in a wider range of patients.

Expanding Treatment Options for All Patients

Endothelial cell therapy offers a potentially groundbreaking solution for patients who are currently ineligible for DMEK. This treatment could significantly expand access to effective care for those with corneal edema, regardless of their individual eye conditions.

The Future of Corneal Edema Treatment

The data from our clinical trials is incredibly promising. We are optimistic that endothelial cell therapy will become a widely accepted and effective treatment for corneal edema, providing patients with improved vision and a better quality of life.

Stay tuned for updates on the US clinical trial and the continued advancements in corneal edema treatment.